Q-omics provides the consensus-scored TFAP2B profile across patient tissues and cancer cell-line models. TFAP2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TFAP2B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TFAP2B RNA expression shows 12,237 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight KIRP, KIRC, and PCPG as cancer lineages where TFAP2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFAP2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFAP2B survival associations across molecular data types. TFAP2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFAP2B RNA expression–survival associations across cancer types. High TFAP2B expression shows unfavorable associations in KIRP, MESO and LGG, but favorable associations in BLCA, UCS and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TFAP2B RNA expression.
This table summarizes TFAP2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TFAP2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFAP2B shows lower tumor expression in KIRC, KICH, KIRP, HNSC and COAD and higher tumor expression in UCEC. The KIRC box plot shows higher TFAP2B RNA expression in normal versus tumor tissue (log2 FC = −3.889, t-test p < 0.001).
This table shows molecular features associated with TFAP2B in patient tissues and cancer cell lines. In patient samples, TFAP2B shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, TFAP2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
